Matthew Davids, MD, MMSc

drmdavids.bsky.social

08 October 2026 16:00

Excited to join the JCO team—will be handling papers focused on lymphoma and CLL! @danafarber.bsky.social

Ian Davis

profiand.bsky.social

08 October 2026 15:59

I was honoured to be asked by @jco-asco.bsky.social Oncology Practice to write this editorial. ascopubs.org/doi/10.1200/...

Fumiko Ladd Chino, MD FASCO

fumikochino.bsky.social

20 July 2026 17:46

Dr Robin Zon's @ascocancer.bsky.social presidential address focused on translating EBM into better outcomes for pts through meaningful investments in tech, advocacy, & community. 🎙️new #JCOOP podcast feat. former ASCO President on leadership & future vision in oncology ascopubs.org/do/roadmap-a...

γδ T cell Forum

forum-gd.bsky.social

14 July 2026 15:07

Intracranial Injection of Investigational Ex Vivo Expanded and Activated Gamma-Delta T Cells Engineered With a Methylguanine-DNA Methyltransferase–Expressing Lentivector in Patients With Primary Glioblastoma #gdTcells @jco-asco.bsky.social

Dana-Farber News

danafarbernews.bsky.social

09 July 2026 15:18

Now in @jco-asco.bsky.social from @danafarber.bsky.social: The eNRGy phase 2 clinical trial improved progression-free survival for previously treated patients with advanced NRG1-positive cholangiocarcinoma. This study led to FDA approval for zenocutuzumab for this population. bit.ly/4eAItuT